• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Characterization of prolactin receptors in human breast cancer.

作者信息

Peyrat J P, Djiane J, Kelly P A, Vandewalle B, Bonneterre J, Demaille A

出版信息

Breast Cancer Res Treat. 1984;4(4):275-81. doi: 10.1007/BF01806039.

DOI:10.1007/BF01806039
PMID:6097324
Abstract

In order to perform measurement of PRL binding and to improve the knowledge of pathophysiological variations in human mammary cancers, we have investigated in detail the binding characteristics of PRL in membranes prepared from these tumors. The optimization of the assay requires the selection of membranous components of light density (less than 1.17); the tracer could be either 125I-PRL after affinity purification on PRL receptors or 125I-hGH without a purification step. It is favorable to utilize a high amount of protein and 200 000 cpm (2 ng) of tracer. Demonstration of the presence of receptors for PRL with a high affinity (Kd= 3 X 10(-10) M) in breast cancer is presented. The hormonal specificity of these receptors is studied: only lactogenic hormones (hGH, oPRL, hPRL, and hPL) are able to compete for binding of 125I-hPRL whereas bGH or insulin are without effect. Considering the known effect of PRL on cell multiplication, it is tempting to suggest that this hormone could have a crucial role in the development of breast tumor in humans and that therapies which would suppress secretion of PRL and GH could be beneficial.

摘要

相似文献

1
Characterization of prolactin receptors in human breast cancer.
Breast Cancer Res Treat. 1984;4(4):275-81. doi: 10.1007/BF01806039.
2
Prolactin (PRL) receptor induction in cultured rat hepatocytes: dual regulation by PRL and growth hormone.培养的大鼠肝细胞中催乳素(PRL)受体的诱导:PRL和生长激素的双重调节
Endocrinology. 1988 Mar;122(3):1151-8. doi: 10.1210/endo-122-3-1151.
3
Specific binding sites for prolactin and growth hormone in the adult rabbit lung.成年兔肺中催乳素和生长激素的特异性结合位点。
Mol Cell Endocrinol. 1987 Jan;49(1):17-24. doi: 10.1016/0303-7207(87)90059-1.
4
Characterization and modulation of growth hormone and prolactin binding in mouse liver.小鼠肝脏中生长激素和催乳素结合的表征与调节
Endocrinology. 1976 Mar;98(3):645-54. doi: 10.1210/endo-98-3-645.
5
Hepatic binding of human and bovine growth hormones and ovine prolactin in the dwarf "little" mouse.侏儒“小”鼠中人类和牛生长激素以及绵羊催乳素的肝脏结合情况
Endocrinology. 1983 Jun;112(6):2032-8. doi: 10.1210/endo-112-6-2032.
6
Prolactin-binding components in rabbit mammary gland: characterization by partial purification and affinity labeling.兔乳腺中的催乳素结合成分:通过部分纯化和亲和标记进行表征
Endocrinology. 1985 Jun;116(6):2612-20. doi: 10.1210/endo-116-6-2612.
7
Modulation of prolactin receptors (PRL-R) by lactogenic and steroid hormones in human breast cancer cells in long-term tissue culture (T-47D).在长期组织培养(T-47D)的人乳腺癌细胞中,催乳素和类固醇激素对催乳素受体(PRL-R)的调节作用。
Anticancer Res. 1989 May-Jun;9(3):631-6.
8
Receptors for lactogenic hormones in the ovine corpus luteum. I: A major discrepancy in the specific binding of radiolabelled ovine prolactin and human growth hormone.绵羊黄体中催乳激素的受体。I:放射性标记的绵羊催乳素和人生长激素特异性结合的一个主要差异。
J Endocrinol. 1987 Jun;113(3):365-74. doi: 10.1677/joe.0.1130365.
9
Membrane modification differentially affects the binding of the lactogenic hormones human growth hormone and ovine prolactin.膜修饰对生乳激素人类生长激素和绵羊催乳素的结合有不同影响。
Proc Natl Acad Sci U S A. 1981 Sep;78(9):5704-7. doi: 10.1073/pnas.78.9.5704.
10
Evidence that non-covalent forces, thiol and disulphide groups affect the structure and binding properties of the prolactin receptor on hepatocytes from pregnant rats.有证据表明,非共价力、硫醇和二硫键基团会影响妊娠大鼠肝细胞上催乳素受体的结构和结合特性。
Biochem J. 1985 Jun 1;228(2):383-90. doi: 10.1042/bj2280383.

引用本文的文献

1
Establishment and characterization of a new cell line (VHB-1) derived from a primary breast carcinoma.源自原发性乳腺癌的新细胞系(VHB-1)的建立与鉴定
J Cancer Res Clin Oncol. 1987;113(6):550-8. doi: 10.1007/BF00390864.
2
The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors.生长抑素类似物善得定(SMS201-995)治疗二甲基苯并蒽诱导的大鼠乳腺肿瘤
Breast Cancer Res Treat. 1990 Nov;17(1):23-32. doi: 10.1007/BF01812681.

本文引用的文献

1
Protein measurement with the Folin phenol reagent.使用福林酚试剂进行蛋白质测定。
J Biol Chem. 1951 Nov;193(1):265-75.
2
THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.高比放射性碘-131标记人生长激素的制备
Biochem J. 1963 Oct;89(1):114-23. doi: 10.1042/bj0890114.
3
Effect of hormones on growth rates of malignant and nonmalignant human mammary epithelia in cell culture.激素对细胞培养中恶性和非恶性人乳腺上皮细胞生长速率的影响。
In Vitro. 1980 Jun;16(6):491-501. doi: 10.1007/BF02626462.
4
Multiple hormone interactions in the developmental biology of the mammary gland.乳腺发育生物学中的多种激素相互作用。
Physiol Rev. 1980 Oct;60(4):1049-106. doi: 10.1152/physrev.1980.60.4.1049.
5
Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture.催乳素的生理浓度可促进培养的人乳腺肿瘤细胞生长。
J Clin Endocrinol Metab. 1983 Apr;56(4):673-7. doi: 10.1210/jcem-56-4-673.
6
Prolactin receptors in human breast cancer.人类乳腺癌中的催乳素受体
Eur J Cancer Clin Oncol. 1982 Nov;18(11):1157-62. doi: 10.1016/0277-5379(82)90097-9.
7
Total prolactin binding sites in human breast cancer biopsies.
Breast Cancer Res Treat. 1981;1(4):369-73. doi: 10.1007/BF01806753.
8
Prolactin binding by human mammary carcinoma: relationship to estrogen receptor protein concentration and patient age.人乳腺癌中催乳素结合:与雌激素受体蛋白浓度及患者年龄的关系。
Breast Cancer Res Treat. 1981;1(3):233-43. doi: 10.1007/BF01806263.
9
Prolactin receptors in human breast tumors.人类乳腺肿瘤中的催乳素受体。
J Natl Cancer Inst. 1982 Mar;68(3):381-3.
10
Correlation between prolactin-receptor interaction, down-regulation of receptors, and stimulation of casein and deoxyribonucleic acid biosynthesis in rabbit mammary gland explants.
Endocrinology. 1982 Mar;110(3):791-5. doi: 10.1210/endo-110-3-791.